2017
DOI: 10.18632/oncotarget.21053 View full text |Buy / Rent full text
|
|

Abstract: Apatinib is a tyrosine kinase inhibitor and vascular endothelial growth factor receptor 2 (VEGFR-2) targeted drug. A phase I clinical trial showed that this agent has antitumor activity in Chinese patients with metastatic gastric cancer (mGC). The aim of this study was to investigate the safety and efficacy of apatinib treatment in patients with mGC.This was an open-label, multicenter, single-arm study involving four institutions in China. We enrolled 42 patients from March 2015 to October 2015 who experienced… Show more

Help me understand this report

Search citation statements

Order By: Relevance
Select...
3
2
0
5
0

Year Published

2019
2019
2022
2022

Publication Types

Select...
5

Relationship

0
5

Authors

Journals

0
5
0
Order By: Relevance
“…Phase I–III clinical trials showed that apatinib improved PFS and overall survival (OS) in patients with advanced gastric or gastroesophageal junction adenocarcinoma for whom standard chemotherapy had failed. Furthermore, apatinib has demonstrated encouraging anti-tumor activities and manageable toxicities in multiple solid tumors, both as a monotherapy and in combination with other drugs 16,3740…”
Section: Discussionmentioning
Create an account to read the remaining citation statements from this report. You will also get access to:
  • Search over 1.2b+ citation statments to see what is being said about any topic in the research literature
  • Advanced Search to find publications that support or contrast your research
  • Citation reports and visualizations to easily see what publications are saying about each other
  • Browser extension to see Smart Citations wherever you read research
  • Dashboards to evaluate and keep track of groups of publications
  • Alerts to stay on top of citations as they happen
  • Automated reference checks to make sure you are citing reliable research in your manuscripts
  • 7 day free preview of our premium features.

Trusted by researchers and organizations around the world

Over 130,000 students researchers, and industry experts at use scite

See what students are saying

rupbmjkragerfmgwileyiopcupepmcmbcthiemesagefrontiersapsiucrarxivemeralduhksmucshluniversity-of-gavle
“…Phase I–III clinical trials showed that apatinib improved PFS and overall survival (OS) in patients with advanced gastric or gastroesophageal junction adenocarcinoma for whom standard chemotherapy had failed. Furthermore, apatinib has demonstrated encouraging anti-tumor activities and manageable toxicities in multiple solid tumors, both as a monotherapy and in combination with other drugs 16,3740…”
Section: Discussionmentioning
“…Thus, the SOX plus apatinib regimen may have been effective in suppressing metastasis. A multicenter phase II study of apatinib treatment for metastatic GC indicated that the drug is effective and safe in patients who failed to respond to two or more prior chemotherapy regimens, and that the toxicities were clinically manageable ( 24 ). A systematic review and meta-analysis showed that apatinib plus chemotherapy is more effective than chemotherapy alone for patients with advanced GC ( 25 ).…”
Section: Discussionmentioning
“…Inevitably, as the patient population grows, the heterogeneity in physical condition, renal and hepatic function brings new challenges. In a phase 2 trial ( 8 ), high incidence of grade 3 to 4 adverse events was observed in patients with metastatic gastric cancer progressed after two lines of chemotherapy who were given 850 mg of apatinib once daily. Dose reduction occurred in nine of 42 patients due to grade 3 or 4 adverse events and treatment discontinuation occurred in eight patients.…”
Section: Introductionmentioning